Bamlanivimab/Etesevimab

巴尼韦单抗/埃特司韦单抗

Report date: 2022/12/27 13:30:23

Base Information

Drug NameBamlanivimab/Etesevimab
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes BamlanivimabEtesevimab
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And CompanyShanghai Junshi Biosciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEuropean CommissionEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A